The S-phase kinase-associated protein-2 (SKP2) plays a key role in ubiquitin-mediated proteolysis, which results in the progression of cells from a quiescence to proliferative state. SKP2 is overexpressed in a variety of tumors. In this study, we used small interfering RNAs (siRNAs) to inhibit the SKP2 expression in lung cancer cells and thereby investigate the role of SKP2 in lung tumorigenesis. Three lung cancer cell lines were transfected with siRNAs targeted against SKP2. SKP2-siRNAs specifically and efficiently reduced the levels of the SKP2 protein by 90% 48 h after transfection in all cell lines. In the A549 and H1792 cells, p27 expression was increased and the increase was inversely proportional to the level of SKP2; cell proliferation was reduced to 12 and 28%, respectively; apoptosis was increased to 36 and 30%, respectively; 36 and 28% of cells accumulated in the sub-G1 phase, respectively; and the population of cells in the G1 phase was decreased to 37 and 41%, respectively. In addition, the SKP2-depleted A549 and H1792 cells showed decreased levels of cyclin E/CDK2. Correspondingly, only 4 and 6% of the treated A549 and H1792 cells had multiple centrosomes, respectively, compared with 43 and 46% of the control cells, respectively. These results imply that SKP2 plays an oncogenic role in lung cancer and that SKP2 silencing may be useful in the treatment of lung cancer.
Introduction
Cell proliferation involves the activation of CDK complexes, the inactivation of the retinoblastoma tumor suppressor protein, and the accumulation of E2F transcription factors (Volm et al., 1998; Kaye, 2002) . In lung tumorigenesis, as in other cancers, disruption of components of this control pathway, either by the activation of oncoproteins or by the inactivation of tumor suppressor proteins, can lead to the loss of growth control that underlies a tumor's development (Brambilla et al., 1999; Kaye, 2002) . Recent studies have emphasized the fact that certain changes in protein stability under the control of selected E3 ubiquitinprotein ligases during the transition from quiescence to proliferation play a key role in cancer development (Lisztwan et al., 1999; Ruffner et al., 2001) . The F-box protein SKP2, a substrate recognition subunit of the SCFSkp2 ubiquitin-protein ligase complex, plays a very important role in this pathway. In particular, SKP2 displays an S-phase-promoting function and has been implicated in the ubiquitin-mediated proteolysis of the CDK inhibitor p27, a dosage-dependent tumor suppressor protein (Carrano et al., 1999; Gstaiger et al., 2001; Kudo et al., 2001) . SKP2 has also been implicated in the ubiquitination of other cell cycle regulatory proteins, such as cyclin E, p130, a member of the retinoblastoma tumor suppressor family, and oncoprotein c-Myc (Yeh et al., 2001; Bhattacharya et al., 2003; von der Lehr et al., 2003) . A further observation in SKP2 transgenic mice has been that its expression is forced in T cells, SKP2 cooperates with the N-ras oncogene, leading to lymphomagenesis (Latres et al., 2001) . In particular, SKP2 cooperates with H-rasG12V to malignantly transform primary rodent fibroblasts (Gstaiger et al., 2001) . Similarly, the overexpression of SKP2 induced hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate (Shim et al., 2003) . Furthermore, increased levels of SKP2 have been found in various cancers and are associated with poor patient survival (Kudo et al., 2001; Chiarle et al., 2002; Lim et al., 2002; Masuda et al., 2002; Yang et al., 2002; Oliveira et al., 2003; Shigemasa et al., 2003) . In addition, cells extracted from SKP2-deficient mice grow more slowly and display aberrant centrosomes (Nakayama et al., 2000; Brinkley, 2001) . Recently, SKP2 was found to be overexpressed in lung cancer cells and its overexpression in tumors with a ras mutation is a poor prognostic marker (Yokoi et al., 2000; Zhu et al., 2004) . However, the tumorigenic role of SKP2 in lung cancer is not yet clear.
Powerful tools are required to precisely define the role of SKP2 in lung tumors. One such tool is small interfering RNAs (siRNAs), which have recently been developed and shown to hold great promise for the analysis of mammalian gene function, because siRNA is a double-stranded form of RNA containing 21-23 bp and is highly specific for the nucleotide sequence of its target in mRNA (Elbashir et al., 2001; McManus and Sharp, 2002) . Therefore, these siRNAs can silence endogenous genes in a sequence-specific manner and reduce the production of specific proteins. Further, the siRNA reaction enables the complete 'knockdown' of a specific protein, which may overcome some of the problems encountered with conventional antisense strategies (Martinez et al., 2002; Rubinson et al., 2003) . An even more exciting potential application of the technology is in gene therapy for various diseases.
In this study, we used siRNAs to inhibit the expression of SKP2 in lung cancer cells and thereby determine the effectiveness of this novel technique in lung tumorigenesis and the role of SKP2 in the proliferation of lung cancer cells. We found that cells treated with SKP2-specific siRNAs had significantly reduced levels of SKP2 and that the depletion of SKP2 resulted in an elevated p27 protein level, decreased cell proliferation, and induction of apoptosis. In addition, SKP2 silencing significantly reduced centrosome amplification in hydroxyurea-treated cancer cells.
Results

Specific inhibition of SKP2 expression by siRNAs
We first determined whether the endogenous level of SKP2 protein in the A549 lung cancer cells could be inhibited by siRNAs. The transfection efficiency of the siRNAs was >90% at a concentration of 40 nM for each cell line after 24 h of transfection. Transfection of the A549 cells with three SKP2-specific siRNAs (siRNA1, siRNA2, and siRNA3) at a concentration of 40 nM reduced the level of SKP2 protein by 20-30% after 24 h of transfection and resulted in a statistically significant reduction in the SKP2 protein level by 60-90% 48 and 72 h after transfection. In contrast, SKP2 protein levels remained unchanged in the PBS mock-treated control cells and in cells transfected with siRNA4 (a scrambled version of siRNA3) or GAPDH-siRNA. GAPDHsiRNA only reduced the expression of GAPDH by 80% 48 h after transfection. Of the three SKP2-specific siRNAs, siRNA3 had the most pronounced inhibitory effect on the production of SKP2 protein (Figure 1a) . Consistent with the Western blot findings, siRNA3 reduced the number of fluorescent cells by up to 90%, with a maximal effect 48 h after transfection (Figure 1b) . Similar observations at different time points were made in H1972 and H460 cells (Figure 1c) . Furthermore, the SKP2 protein reduction occurred in a dose-dependent manner from 1 to 40 nM. At 40 nM, siRNA had a significant inhibiting effect on the production of SKP2 protein (Po0.005), but there was no statistically significant difference in the reduction in the SKP2 protein level between 40 and 90 nM (P>0.005). To determine whether the inhibition of SKP2 expression could be increased by a combination of different siRNAs at lower concentrations, we cotransfected A549 cells with siRNA1, siRNA2, and siRNA3. SKP2 protein production was completely abolished in the cotransfected cells at a concentration of each siRNA of Figure 1 siRNAs against SKP2 specifically inhibit its expression. (a) A549 lung cancer cells were transfected with SKP2-siRNAs 1-4, GAPDH-siRNA, or PBS. Western blot analysis of protein expression was performed 48 h after transfection. The histogram shows the inhibition rate of SKP2 production. The same filter was also probed with b-actin antibody to control for even loading. (b) At 48 h after transfection with SKP2-siRNA3, A549 cells were examined with SKP2 antibody, followed by FITC-conjugated secondary antibody, and analysed using fluorescence microscopy. SKP2 antibody bound to the expressed protein (green); nuclei were stained with DAPI (blue). 15 nM, whereas SKP2 production was inhibited by 90% using 90 nM siRNA3. These data suggest that siRNAs can efficiently and specifically inhibit the expression of the target gene in lung cancer cells.
Depletion of SKP2 resulted in elevated p27 protein level, decreased cell proliferation, and induction of apoptosis
We also examined the level of the p27 protein in the three cell lines transfected with siRNA3. The level of the p27 protein was increased in the transfected A549 and H1792 cells, and the level was inversely proportional to the level of SKP2. In contrast, there was no change in p27 production in the H460 cells even though SKP2 expression was dramatically reduced in the cells after transfection (Figure 2a ). We next examined the effect of siRNA transfection on cancer cell proliferation by determining the viability of cells using 3-(4,5-dimethylthiazol-2-yl)-2,5,-diphenyl tetrazolium bromide (MTT) staining at 24, 48, and 72 h after transfection.
Only 12 and 28% of A549 and H1792 cells, respectively, transfected with siRNA3 survived 48 h after the transfection compared with PBS mock-treated controls, whereas the growth of cells transfected with siRNA4 was not affected (Figure 2b ). In contrast, H460 cell proliferation was not significantly inhibited in response to siRNA3 even at the highest concentration (90 nM). These data showed that there was a clear association between reduced levels of SKP2 and elevated levels of p27, which inhibited cell proliferation in certain siRNAtransfected cancer cells (i.e., A549 and H1792).
To further investigate the observed inhibitory effects of siRNAs on tumor cell proliferation as they relate to cell death pathways, we examined whether the downregulation of endogenous SKP2 could induce apoptosis and what impact SKP2 depletion had on cell cycle kinetics in the siRNA3-transfected A549, H1792, and H460 cells by FACS using the terminal deoxynucleotidyltransferase dUTP nick-end labeling (TUNEL) reaction. Apoptosis was induced in siRNA-transfected A549 and H1792 cells. Specifically, more than 36% of A549 cells and more than 30% of H1792 cells were apoptotic 48 h after siRNA transfection, whereas only 7% of the same two cell lines treated with PBS or siRNA4 alone showed apoptosis (Figure 3a) . Furthermore, a significant increase (36 and 28%, respectively, Po0.05) in the sub-G1 apoptotic peak was seen in the transfected A549 and H1792 cells, compared with only a 6% increase in the control cells. A significant inhibition in the G1 phase was also found in the transfected A549 and H1792 cells (36 and 40%, respectively, Po0.05), compared with the findings in the PBS control or siRNA4-treated cells (70%). In contrast, the siRNA3-treated H460 cells did not show any change in either apoptosis or cell cycle kinetics ( Figure 3b ). To shed light on the mechanism of apoptosis and to determine whether siRNA-SKP2 might upregulate the interferon cascade, we measured the activation of caspase 3 and 8 in the three lung cancer cell lines treated with siRNA3, siRNA4, and PBS using Western blotting. Caspase 8 had an epistatic effect on other caspases, including caspase 2, 3, and 9, in the interferon caspase cascade, whereas caspase 3 is downstream in this series of events and is considered to catalyse a common executional step in all apoptotic pathways (Dai and Krantz, 1999; Thyrell et al., 2002) . The activation products of caspase 8, p43/31 and p18, were all clearly observed in the A549 and H1792 cells treated with siRNA3 ( Figure 4a ). Caspase 3 was also clearly upregulated and activated in these two SKP2-depleted cell lines, as shown by the cleavage of endogenous caspase 3 to the active form (p17) (Figure 4b ). Furthermore, 32 and 40% of the A549 and H1792 cells, respectively, showed confluence, whereas the PBS mock-infected control cells showed complete confluent 48 h after siRNA transfection. Finally, fluorescence microscopy showed that fragmental nuclei formed in 26 and 33% of the SKP2-depleted A549 and H1792 cells, respectively, compared with only 1% of the PBS mock-infected control cells or siRNA4-transfected cells (Figure 4c ). These phenotypes were consistent with the findings of increased apoptosis, an increased population of cells in the sub-G1 population, and the activation of caspase 3 and 8 in the A549 and H1792 cells transfected with SKP2-siRNAs. However, 
Depletion of SKP2 inhibited centrosome duplication and amplification in lung cancer cells
To analyse the effect of SKP2 inhibition on centrosome aberrations in lung cancer cells, A459, H1792, and H460 lung cancer cells were treated with siRNA1, siRNA2, and siRNA3, at a concentration of 40 nM, and hydroxyurea was added 24 h later. After 24 h of hydroxyurea treatment, all of the cells had almost completely arrested in the S-phase. We then checked the expression levels of SKP2, p27, CDK2, and cyclin E using Western blotting, because cyclin E/CDK2 appears to play a critical role in centrosome duplication and separation (Dao et Bloom and Pagano, 2003) . We also used immunofluorescence staining with g-tubulin, a centrosome-specific marker, to detect centrosomes at 24 h. The transfection efficiency was determined by examining the Cy3-fluorescence cells in the Cy3-labeled siRNA-transfected cell population under a fluorescence microscope. The transfection efficiency of the siRNAs was >90% after 24 h of transfection. As shown in Figure 5a , the levels of SKP2, cyclin E, and CDK2 were decreased by 90, 94, and 96% in A549 cells, and by 92, 98, and 90% in H1792 cells, respectively, whereas the level of p27 was increased by threefold and fourfold in the siRNA3-treated A549 and H1792 cells, respectively, compared with the levels in the PBS mock-infected control cells or siRNA4-transfected cells. In contrast, the siRNA3-treated H460 cells did not show any significant change in the p27, cyclin E, and CDK2 levels, although the SKP2 level was decreased by 93%. In addition, only 5 and 6% of siRNA3-treated A549 and H1702 cells had more than two centrosomes, whereas 43 and 46% of PBS control A549 and H1702 cells had multiple centrosomes. In contrast, the numbers of centrosomes remained unchanged in the siRNA3-treated H460 cells, compared with the PBS mock-treated and the siRNA4-treated H460 cells (Figure 5b and c) . Of the three SKP2-specific siRNAs, siRNA3 had the most pronounced inhibitory effect on the reduction of SKP2 protein, the accumulation of p27, and the subsequent downregulation of cyclin E/CDK2.
We next examined whether the centrosome inhibition resulting from SKP2 depletion affected mitotic spindle formation and led to sister chromatid separation. In this experiment, the A459, H1792, and H460 cells were treated with specific SKP2-siRNAs, and 24 h later, nocodazole was added for 16 h to arrest the cells in the M-phase. Dual g-tubulin labeling for centrosomes and a-tubulin labeling for spindles showed that PBS mockinfected control cells and H460 cells treated with specific siRNAs had bipolar mitotic spindles containing both central and astral microtubules with a centrosome at each spindle pole (Figure 6a ). In contrast, the mitotic spindles in specific siRNAs-treated A459 and H1792 cells showed poorly focused convergence, broad microtubules, and centrosomes largely devoid of astral microtubules. In addition, 19 and 16% of specific siRNA-treated A459 and H1792 cells failed to undergo complete cytokinesis, respectively; cells were connected by a cytoplasmic bridge, as revealed by a-tubulin (Figure 6b ). Additionally, a higher proportion of SKP2-depleted A459 and H1792 cells than control cells displayed a dumb-bell-like DNA structure (Po0.05), indicating that sister chromatids had not completely separated after siRNA was added (Figure 6c ). Furthermore, there was an increased number of cells with multiple nuclei in the siRNA-treated cells than in the control cells (Po0.05) (Figure 6d ). There was no significant difference between specific siRNA-treated and PBS mock-infected H460 cells in term of mitotic spindles and cytokinesis. Our data therefore suggest that depriving cells of SKP2 led to an upregulation of p27 and downregulation of CDK2 and cyclin E in siRNA-transfected lung cancer cells, which consequently showed inhibited centrosome amplification and increased errors in spindle positioning, cytokinesis, and chromatid separation.
Discussion
Our study showed that the transfection of cancer cells with siRNAs targeted against the SKP2 gene can effectively reduce SKP2 gene expression and produce antiproliferative effects in lung cancer cells. Neither a scrambled version of siRNA nor siRNA targeted to GAPDH had any effect on the level of SKP2 protein, suggesting that the effect of siRNAs was sequence specific. Our results therefore imply that siRNA is a functional pathway with biologic effects on lung cancer cells.
Although all three sets of siRNAs targeted to different regions of SKP2 inhibited SKP2 production, one of the siRNAs had the most potent silencing effect, which was consistent with data from previous studies showing that there are variations in the effectiveness of different siRNAs targeting the same gene (Elbashir et al., 2001) . This suggests that the exact site targeted in the RNA is a key factor in silencing the target gene. A particularly interesting finding was that although the inhibition was dose-dependent, above a certain concentration, simply increasing the siRNA concentration did not enhance inhibition. A combination of different siRNAs at low concentrations did, however, have a stronger inhibitory effect on SKP2 levels than did the single most potent siRNA at a high concentration, suggesting that the combination had additive or synergistic effects. Using a lower concentration of siRNA to achieve the most potent inhibitory effect is one of the most attractive features of siRNA-based gene silencing. This is because only a high concentration of antisense oligonucleotides can inhibit SKP2 expression in lung cancer cells (Yokoi et al., 2000 (Yokoi et al., , 2003 , but such concentrations are potentially toxic. As siRNA effectively reduced the target gene level without causing generalized toxicity, this result implies that siRNA has obvious advantages over an antisense strategy in reducing gene expression, and therefore this approach has potential application in gene therapy for lung tumors.
SKP2 has been found to be overproduced in 83% of small cell lung cancer cell lines and in 74% of non-small cell lung cancers (Yokoi et al., 2000; Zhu et al., 2004 ). In Figure 6 Effect of centrosome inhibition resulting from SKP2 depletion on mitotic spindle formation and cytokinesis. The H1792 cells were treated with SKP2-siRNA3 or SKP2-siRNA4, and 24 h later, nocodazole was added for 16 h to arrest the cells in the Mphase, after which they were examined using dual g-tubulin labeling for centrosomes and a-tubulin labeling for spindles. Nuclei were stained with DAPI. All the left panels show the SKP2-siRNA3-treated cells; all the right panels show the SKP2-siRNA4-treated cells. (a) SKP2-siRNA4-treated cells have bipolar mitotic spindles containing both central and astral microtubules (green) with a centrosome (red) at each spindle pole, while the mitotic spindles in SKP2-siRNA-treated cells show poorly focused convergence, broad microtubules (green), and only one centrosome (red). the current study, the depletion of SKP2 in A549 and H1792 lung cancer cells was associated with elevated p27 expression, which was followed by the induction of apoptosis, decreased cell proliferation, and inhibition of the G1 phase. This implies that the overexpression of SKP2 is a primary cause of the downregulation of p27 in certain lung cancers, and provides strong evidence that SKP2 is an oncogene and is functionally activated during the pathogenesis of lung cancer. H460 cells, however, showed no elevated levels of p27 and reduced cell proliferation, although their SKP2 expression was dramatically inhibited, suggesting that other factors, such as additional molecular events or alternative pathways, contribute to the downregulation of p27 expression in a subset of tumor cells (Hara et al., 2001; Malek et al., 2001; Connor et al., 2003) . For example, the deregulation of Cks1, a cofactor of SKP2, might cooperate with SKP2 in the process of p27 degradation (Harper, 2002) . Future studies are needed to explore these possibilities. We also demonstrated that the depletion of SKP2 by siRNA induces lung cancer cell apoptosis, followed by the inhibition of cell proliferation. How might the depletion of SKP2 induce cancer cell apoptosis? A possible explanation is offered by the elevated p27 level in SKP2-depleted A549 and H1792 cells, which leads to the activation of caspase 3 and 8, a significant inhibition of the G1 phase, an increase in the population of cells in the sub-G1 phase, and hence an apoptotic phenotype. In contrast, there is no increased level of p27 and no apoptosis in SKP2-depleted H460 cells. This observation is in agreement with those in recent reports suggesting that the inhibition of SKP2-induced apoptosis is characterized by an elevated level of p27, an increase in the sub-G1 population, and a decrease in the G1 phase (Yokoi et al., 2000; Gstaiger et al., 2001) . The findings of a high level of p27 and low G1 cell population resulting from inhibited SKP2 are also consistent with the function of p27 as a key regulator of G1 progression, serving as both an inhibitor of CDK2 activity in the G0 and early G1 phases and an assembly factor for cyclin D-CDK4/6 complexes in the early G1 phase (Foster et al., 2003) . Therefore, our data imply that the apoptosis seen in A549 and H1792 cells occurred via the p27 degradation pathway. In addition, the upregulation of p27 has been proven to induce apoptosis and inhibit high proliferative activity in other cancer cells (Slingerland and Pagano, 2000) . Thus, SKP2-siRNA could inhibit tumor growth by controlling the level of SKP2, which could in turn activate the p27 pathway that leads to apoptosis, thereby reducing DNA synthesis and cell proliferation, and hence inhibiting the malignant process in certain lung cancer cells.
Loss of centrosome duplication control leading to centrosome amplification has been found in a variety of malignant tumors, including lung cancers (Brinkley, 2001; Nigg, 2002; Masuda et al., 2002) . It plays a critical role in causing genetic instability in tumor cells because the centrosome contributes to spindle abnormalities and disturbed chromosome segregation (Lingle et al., 1998; Pihan et al., 1998) . In previous studies, we have shown that centrosome amplification can be present in earlystage bladder cancer and that amplification of the oncogene STK15, which is located in the centrosome, is associated with aneuploidy and clinically aggressive bladder cancers (Sen et al., 2002; Jiang et al., 2003) . Indeed, centrosome abnormalities have been considered one possible cause of cancer (Brinkley, 2001) .
The mechanisms that lead to centrosome abnormalities are not yet clear, although the loss of tumor suppressors, including p53, p21CIP1, GADD45, and BRCA1, and the activation of oncogenes such as ras, STK15, and MAPKK have been shown to trigger centrosome amplification and aneuploidy in cancer cells (Zhou et al., 1998; Wang et al., 1999; Saavedra et al., 2000; Deng, 2002; Tarapore and Fukasawa, 2002) . Recent studies have implied that CDKs and ubiquitin ligase cell cycle regulators play fundamental roles in controlling the centrosome cycle (Freed et al., 1999; Hinchcliffe et al., 1999; Lacey et al., 1999; Meraldi et al., 1999; Vidwans et al., 1999; Okuda et al., 2000) . For example, cyclin E/CDK2 is important in centrosome duplication and centriole separation in somatic cells, as indicated by the fact that cyclin E/CDK2 activity rises shortly before the onset of S phase, which is when centrioles duplicate. More importantly, p27 can block cyclin E/CDK2 activity, further inhibiting the duplication of centrosomes, suggesting that the effect of cyclin E/Cdk2 on centrosome duplication is under the control of p27 (Dao et al., 1998; Lacey et al., 1999; Bloom and Pagano, 2003) . SCF ubiquitin ligases have been suggested to have a specific role in the centrosome duplication cycle; this was suggested by the discovery that the SKP1 or SKPa protein, another core component of the SCF ubiquitin ligase, regulates centriolar splitting during G1/S transition and centrosome duplication (Freed et al., 1999; Gstaiger et al., 1999; Piva et al., 2002; Murphy, 2003) . Further insight has come from Nakayama et al. (2000) , who found that 38% of mouse fibroblasts deficient in SKP2 contained supernumerary centrosomes, which suggests that SCF ubiquitin ligases are important in centrosome reduplication. In the present study, we found that SKP2 depletion induced increased levels of p27 and reduced expression of cyclin E and CDK2 in lung cancers. Consequently, the number of centrosomes in the SKP2-depleted cancer cells was significantly decreased, and this was followed by the formation of abnormal mitotic spindle poles and the failure of productive cytokinesis and chromatid separation. Our findings may establish a causal link between SKP2 activation and centrosome abnormalities in human tumorigenesis and provide support for the centrosome cycle and the chromosome replication cycle being controlled by the SCF ubiquitin ligase cell cycle regulatory pathway. Although more studies are necessary to clarify the precise mechanism, such as studies forcing the expression of SKP2 in normal epithelial bronchial cells so that the resultant centrosomal change can be observed, we speculate that a reduced level of SKP2 in cancer cells causes the accumulation of p27 and the subsequent downregulation of cyclin E/CDK2. This in turn leads to inhibition of centrosome amplification and spindle abnormalities, which may result in failed cytokinesis and chromosome loss or missegregation. The mechanism underlying this observation may be related to the ability of the SKP2-p27-Cdk1/2 axis to control DNA synthesis and mitosis, in which p27 is the principal downstream effector of the SKP2 ubiquitin ligases (Pagano, 2004) , because a reduced level of SKP2 in two of the cancer cell lines caused the accumulation of p27 and then the downregulation of cyclin E/CDK2, which in turn led to the inhibition of centrosome amplification. In contrast, a third cell line showed no increased in the level of p27 and no subsequent downregulation of cyclin E/CDK2 and centrosome amplification inhibition, although its SKP2 expression was dramatically inhibited.
Our study findings are consistent with some results from Nakayama et al. (2000) , who demonstrated that the cells extracted from Skp2 (À/À) mice showed increased upregulation of p27. Our observation of centrosomal duplication inhibition resulting from cyclin E/CDK2 downregulation is also in agreement with their conclusion that the centrosome overduplication resulted from overexpression of cyclin E. However, they found that cells extracted from Skp2 (À/À) mice had elevated cyclin E expression and unchanged CDK2 expression and contained a considerable number of centrosomes, whereas we observed that the SKP2-depleted cancer cells treated with siRNA-SKP2 had decreased cyclin E/CDK2 expression and contained considerably fewer centrosomes. One possible explanation for this apparent discrepancy is that the functional role of cyclin E in development differs from its role in tumorigenesis (Nakayama et al., 2000 (Nakayama et al., , 2004 . For example, the marked accumulation of cyclin E in Skp2 (À/À) mice appears to be the free form of the protein and regulation of the cyclin E, and therefore may be independent of p27 accumulation (Nakayama et al., 2000 (Nakayama et al., , 2004 . This is shown by the fact that the overexpression of p27 caused by infecting Skp (À/À) mutant cells with a recombinant adenovirus encoding p27 did not result in any change in the level of cyclin E expression (Nakayama et al., 2000) . During development, the elevated levels of free cyclin E might therefore compromise tissue organization in the developing embryo but not induce carcinogenesis, as suggested by the fact that no cancer was found in the mice up to 10 months of age (Nakayama et al., 2000) . Furthermore, the free form of cyclin E does not form a complex with CDK2 and therefore does not contribute to the kinase activity of CDK2 (Nakayama et al., 2000) . In SKP2-depleted tumor cells, however, there is a marked increase in p27, a subsequent decrease in cyclin E/CDK2, and inhibition of centrosome overduplication, suggesting that the downregulation of cyclin E/CDK2 and p27 plays a critical role in the tumorigenesis (Pagano, 2004) . In fact, high cyclin E/CDK2 and low p27 expressions are common in a variety of tumors including lung cancer, and researchers have suggested that they might serve as proliferative and prognostic markers in patients with lung adenocarcinoma (Kawana et al., 1998; Fukuse et al., 2000) .
Our data not only confirmed the importance of p27 in tumorgenesis but also demonstrated that the reduced level of SKP2 in cancer cells causes downregulation of cyclin E/CDK2, and implied that SKP2 plays an oncogenic role in causing centrosome abnormalities that are critical in causing genetic instability in tumor cells. Furthermore, although p27 has been considered a useful target for gene therapy (Park et al., 2001) , SKP2 might be a better potential therapeutic agent for targeting the ubiquitin-proteasome pathway, and silencing SKP2 using the siRNA technique might provide another powerful therapeutic strategy.
In conclusion, our study strongly suggests that RNA has an inhibitory effect on SKP2 expression and the biologic consequences in lung cancer result from an RNA-silencing mechanism. The data therefore imply an oncogenic role for SKP2 in lung cancer and an antineoplastic role for SKP2 silencing. Future experiments are needed to develop an efficient SKP2-siRNA delivery system and evaluate the in vivo effects of SKP2-siRNA on lung tumors.
Materials and methods
siRNA preparation
Several siRNAs targeting the SKP2 mRNA sequence (National Center for Biotechnology Information, Accession Number NM 005983) were identified using criteria published on Ambion's (Austin, TX, USA) Web site. These included siRNA1, which corresponds to positions 22-44 of the SKP2 open reading frame; siRNA2, which corresponds to positions 422-444; and siRNA3, which corresponds to positions 908-930. We also designed siRNA4, a scrambled version of siRNA3. siRNA4 contains the same nucleotides as siRNA3, but in an irregular sequence. The sequences for silencing the GAPDH gene region were used as the control siRNA. All siRNAs were prepared using a transcription-based method with the silencer siRNA construction kit (Ambion) according to the manufacturer's instructions.
Cell culture, transfections, and transfection efficiency
Lung cancer cell lines A549, H1792, and H460 were cultured in DMEM supplemented with 10% FBS at 371C in 5% CO 2 . At 1 day prior to transfection, cells were seeded at 1 Â 10 6 cells per 25-cm 2 culture flasks and transfected using the lipid transfection protocol (Ambion) with siRNAs at a concentration of 40 nM (except in dose-dependence experiments, in which the concentrations of siRNAs ranged from 1 to 90 nM, and the experiment determining the activation of caspase 3 and 8 in SKP2-siRNA-transfected cells, in which the concentrations of siRNA3 and siRNA4 were 40 and 90 nM, respectively). Cells were incubated for 4 h with siRNAs or PBS (control cells) in lipid transfection reagent. After this, one-third of the transfection volume of fresh culture medium with 10% FCS was added. Cells were harvested 24, 48, and 72 h after the transfection, protein expression was evaluated and the immunofluorescence assay and FACS analysis were performed. To synchronize cells, 24 h after transfection, cells were incubated either with 4 mM hydroxyurea for 24 h to arrest the cells in the S phase or with 0.1 mM nocodazole for 16 h to arrest the cells in the M phase. The Fluorescein siRNA Labeling Kit (Ambion) was used to label chemically synthesized siRNAs with Cy3. Cells transfected with the labeled siRNAs were counted using a hemocytometer under a Leica microscope (Leica Microsystems, Inc., Bannockburn, IL, USA). The cell number was calculated relative to a nontreated cell population and graphed to determine transfection efficiency.
Cellular proliferation assays
The inhibition of cell growth by siRNAs was determined by MTT staining. In brief, cells were grown in 96-well plates and transfected with siRNA. At 24, 48, and 72 h after the transfection, a one-tenth volume of MTT solution (5 mg MTT/ml PBS) was added, and each plate was incubated for 4 h. The medium was then removed, and precipitates were dissolved in 100 ml of N,N-dimethylformamide lysis buffer (Sigma-Aldrich, St Louis, MO, USA). The resultant solution was read at A 595 with a microreader. The growth rate was plotted against the percentage of viable cells in PBS-treated controls (a value arbitrarily set at 100%).
Apoptosis and cell cycle analysis
Apoptosis was analysed by FACS using a TUNEL reaction with FITC-labeled dUTP (Boehringer Mannheim Biochemicals, Mannheim, Germany). Cells were seeded onto six-well plates (1 Â 10 6 cells/well) and transfected with siRNAs. PBS was used as the control agent. Cells were harvested at designated times, fixed in 1% formaldehyde, and permeabilized in 70% ethanol. Cells were then resuspended in TUNEL reaction mixture and incubated for 60 min at 371C. Cells were resuspended in 500 ml of propidium iodide solution (Boehringer Mannheim Biochemicals). The fluorescence was read on a Coulter Epics XL (Beckman-Coulter, Brea, CA, USA). Green fluorescence was a marker of DNA fragmentation and apoptosis, and red fluorescence a marker of DNA content and cell cycle status.
Western blot analysis
Cells were lysed at a density of 5 Â 10 4 cells/ml in lysis buffer (1% Triton X-100, 1 mM EDTA, 150 mM NaCl, and 50 mM Tris-HCl) on ice for 10 min. Equal amounts of lysate were separated by SDS-PAGE on an acrylamide gel. Proteins were transferred to a nitrocellulose membrane (Pierce Biotechnology, Inc., Rockford, IL, USA) and incubated with antibodies specific to SKP2, p27, GAPDH, cyclin E, CDK2, and caspase 3 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and with antibody to caspase 8 (AXXORA, LLC., San Diego, CA, USA) for 3 h each. The membranes were then incubated with the appropriate secondary antimouse or antirabbit horseradish peroxidase-conjugated antibodies (Bio-Rad, Inc., Hercules, CA, USA) for 2 h. Immunocomplexes were detected using an enhanced chemiluminescence reagent (Amersham Pharmacia Biotech, Buckinghamshire, UK). An anti-b-actin blot was created in parallel as a loading control.
Immunofluorescence assay
Immunofluorescence staining was performed to visualize the spindle apparatus (a-tubulin) and centrosomes (l-tubulin) using the following methods. First, the cells were incubated with anti-a-tubulin or anti-l-tubulin primary antibody (SigmaAldrich) for 1 h, followed by incubation with FITC-or Cy3-conjugated anti-mouse or anti-rabbit Ig secondary antibody (Molecular Probes, Inc., Eugene, OR, USA) for 30 min. DNA was stained with 4 0 ,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). Finally, cells were examined with a Leica microscope (Leica Microsystems, Inc.). All images were recorded with Hamamatsu 9792-95 digital camera (Bridgewater, NJ, USA) and processed with OpenLab image software (Improvision, Coventry, UK).
Statistical analysis
All the experiments were repeated at least three times with each treatment performed in triplicate. Means of normalized to b-actin signal intensities on Western blots, along with 95% confidence intervals, were calculated. The MTT results were analysed using the General Linear Models of Statistica (StatSoft, Inc., Tulsa, OK, USA). FACS analyses were performed three times for each cell type. All P-values were two-sided, and Po0.05 was considered statistically significant. Abbreviations CDK, cell cyclin cyclin-dependent protein kinase; SKP2, Sphase kinase-associated protein-2; siRNAs, small interfering RNAs; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5,-diphenyl tetrazolium bromide; FACS, fluorescence-activated cell sorting; TUNEL, terminal deoxynucleotidyltransferase dUTP nick-end labeling; DAPI, 4 0 ,6-diamidino-2-phenylindole.
